<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20101220005426N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-29</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>A comparison of two stem cells utilization methods; intravenous and intra alveolar injection by bronchoscope on outcome of severe lung contusion</public_title>
      <acronym></acronym>
      <scientific_title>A comparison of two stem cells utilization methods; intravenous and intra alveolar injection by bronchoscopy on outcome of severe lung contusion in patients admitted to intensive care unit (ICU)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65529</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize people to three groups, the block randomization method is used in such a way that blocks of size 6 are used. R statistical software is used for random block allocation, Blinding description: It is a one-way blind method in which stem cells are injected by an ICU specialist. Examination of pneumonia (CPIS criteria, clinical history, clinical examination and chest x-ray) will be done by an anesthesiologist, and the arterial oxygen pressure will be checked by the senior ICU nurse who does not know the type of cell injection to the patients. Also, laboratory tests will be done by a technician who's not aware of the interventions will be made.</study_design>
      <phase>2</phase>
      <hc_freetext>lung contusion.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: The first group will receive 60 million dental pulp stem cells intravenously in addition to common supportive treatments. Intervention 2: Intervention group 2: The second group, in addition to common supportive treatments, 60 million dental pulp stem cells are pushed by a bronchoscope inside the lung alveoli in the contusion area (based on CT scan findings). Intervention 3: Control group: They will only be treated by usual treatments.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Ahmadinejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Bahonar Hospital, Qarani St, Valiasr Crossroads, Shariaati St, Kerman</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 0223 5011</telephone>
        <email>mehdia50@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Ahmadinejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Bahonar Hospital, Qarani St, Valiasr Crossroads, Shariaati St, Kerman</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 0223 5011</telephone>
        <email>mehdia50@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The pressure of arterial oxygen to inspiratory oxygen should be less than 180(PaO2/FIO2&lt;180)
Bilateral infiltration with pulmonary edema in anterior lung radiography
Pulmonary contusion greater than 40% in chest CT scan
The need to transfer to the intensive care unit due to respiratory failure
Criteria 1-4 must all be present within a 24-hour period at the time of study entry</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>More than 96 hours have passed since the patient's ARDS trauma
Pregnant or lactating woman
Presence of any active malignancy (other than nonmelanoma skin cancer) that requires treatment within 2 years
Any irreversible disease such as malignancies and a condition with a 50% chance of death within the next six months
Moderate to severe liver disorder based on Child-Puff criteria&lt;12
chronic obstructive pulmonary disease(COPD)
The patient has undergone a lung transplant
The patient's lack of consent, or if the patient is unable to answer, the patient's guardian's lack of consent
A patient who is not expected to be alive in the next 24 hours according to the Apache criteria
Class III or IV pulmonary hypertension
Pulmonary embolism or deep vein thrombosis in the past three months
Brain trauma
Transfusion of large volume of blood (injection of more than 10 units of blood in the last 24 hours)
The presence of heart failure, kidney and diabetes
Patients in a state of shock and previous concurrent contusion</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S27.32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Contusion of lung</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: The first group will receive 60 million dental pulp stem cells intravenously in addition to common supportive treatments</i_keyword>
      <i_keyword>Intervention group 2: The second group, in addition to common supportive treatments, 60 million dental pulp stem cells are pushed by a bronchoscope inside the lung alveoli in the contusion area (based on CT scan findings).</i_keyword>
      <i_keyword>Control group: They will only be treated by usual treatments</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Arterial oxygen pressure to inspiratory oxygen pressure ratio. Timepoint: The ratio of arterial oxygen pressure to inspiratory oxygen pressure at the beginning of the study (before the start of the intervention) and 1, 4 and 10 days after cell injection in intervention and control groups. Method of measurement: ABG.</prim_outcome>
      <prim_outcome>Average duration (days) of ventilation. Timepoint: After the intervention, daily until the end of hospitalization. Method of measurement: check list.</prim_outcome>
      <prim_outcome>Death. Timepoint: death between 28 and 60 days after the start of the study. Method of measurement: Check list.</prim_outcome>
      <prim_outcome>Average period of stay in ICU. Timepoint: The average period of stay in the ICU between 28 and 60 days after the start of the study in the intervention and control groups. Method of measurement: check list.</prim_outcome>
      <prim_outcome>Need for intubation. Timepoint: Need for intubation during the study. Method of measurement: Check list.</prim_outcome>
      <prim_outcome>Forced expiratory volume in the first one second to the forced vital capacity(FEV1/FVC). Timepoint: forced expiratory volume in the first one second to the forced vital capacity(FEV1/FVC) at the 1, 3 and 6 months after the start of study in intervention and control groups. Method of measurement: spirometry.</prim_outcome>
      <prim_outcome>Forced vital capacity. Timepoint: Forced vital capacity at the 1, 3 and 6 months after the start of study in intervention and control groups. Method of measurement: spirometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-25</approval_date>
        <contact_name>Ethic committee, Kerman University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for research, Kerman University of Medical Sciences, Jahad street Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
